Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00010413 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus
A Phase 2 study of Pemphigus, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT00010413: Completed Phase 2 study of Pemphigus, sponsored by Johns Hopkins University.
NCT00010413 is a Phase 2 study of Pemphigus that has completed, run by Johns Hopkins University. The registered enrollment target is 35 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00010413, a Phase 2 study of Pemphigus, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
OBJECTIVES: I. Determine the response rate and 1-year event-free survival of patients with refractory pemphigus treated with high-dose cyclophosphamide.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- DRUG filgrastim
Study Locations (1)
Maryland
- Johns Hopkins University School of Medicine - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 1999-04 |
| Phase | Phase 2 |
What the finished NCT00010413 record still lists
NCT00010413 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Pemphigus appearing as the primary indexed condition, and to 2 interventions - of which cyclophosphamide is the first listed.
NCT00010413 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00010413 about?
NCT00010413 is a clinical study titled "Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus". OBJECTIVES: I. Determine the response rate and 1-year event-free survival of patients with refractory pemphigus treated with high-dose cyclophosphamide.
What is the current status of trial NCT00010413?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 1999-04.
What conditions does trial NCT00010413 study?
This clinical trial studies the following conditions: Pemphigus.
What interventions are being tested in trial NCT00010413?
The interventions under investigation include: cyclophosphamide (DRUG), filgrastim (DRUG).
Who is sponsoring clinical trial NCT00010413?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00010413 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00010413's enrollment target sits among peer trials
35 1524th of 2000 higher than 462 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia